


# EXHIBIT 1



U. S. PATENT

**THE UNITED STATES OF AMERICA**

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 25, 2015

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THIS OFFICE OF:

U.S. PATENT: *8,497,393*

ISSUE DATE: *July 30, 2013*

By Authority of the  
Under Secretary of Commerce for Intellectual Property  
and Director of the United States Patent and Trademark Office



T. LAWRENCE  
Certifying Officer



US008497393B2

(12) **United States Patent**  
**Batra et al.**(10) **Patent No.:** **US 8,497,393 B2**  
(45) **Date of Patent:** **Jul. 30, 2013**

- (54) **PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®**
- (75) **Inventors:** **Hitesh Batra**, Herndon, VA (US); **Sudersan M. Tuladhar**, Silver Spring, MD (US); **Raju Penmasta**, Herndon, VA (US); **David A. Walsh**, Palmyra, VA (US)
- (73) **Assignee:** **United Therapeutics Corporation**, Silver Spring, MD (US)
- (\* ) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

2004/0176645	A1	9/2004	Moriarty et al.
2005/0085540	A1	4/2005	Phares et al.
2005/0101608	A1	5/2005	Santel
2005/0165111	A1	7/2005	Wade et al.
2005/0282901	A1	12/2005	Phares et al.
2005/0282903	A1	12/2005	Wade et al.
2007/0078095	A1	4/2007	Phares et al.
2007/0078182	A1	4/2007	Phares et al.
2008/0200449	A1	8/2008	Olschewski et al.
2008/0249167	A1	10/2008	Phares et al.
2008/0280986	A1	11/2008	Wade et al.
2009/0036465	A1	2/2009	Rosigno et al.
2009/0124697	A1	5/2009	Cloutier et al.
2009/0163738	A1	6/2009	Batra et al.
2009/0281189	A1	11/2009	Walsh
2010/0076083	A1	3/2010	Olschewski
2010/0282622	A1	11/2010	Phares
2011/0092599	A1	4/2011	Wade et al.
2011/0118213	A1	5/2011	Phares et al.
2011/0144204	A1	6/2011	Jeffs et al.
2011/0224236	A1	9/2011	Rothblatt et al.
2011/0319641	A1	12/2011	Batra et al.
2012/0004307	A1	1/2012	Wade et al.
2012/0010159	A1	1/2012	Rothblatt et al.

(21) **Appl. No.:** **13/548,446**(22) **Filed:** **Jul. 13, 2012**(65) **Prior Publication Data**

US 2012/0283470 A1 Nov. 8, 2012

**Related U.S. Application Data**

(63) Continuation of application No. 12/334,731, filed on Dec. 15, 2008, now Pat. No. 8,242,305.

(60) Provisional application No. 61/014,232, filed on Dec. 17, 2007.

(51) **Int. Cl.**  
**C07C 62/00** (2006.01)  
**C07C 65/00** (2006.01)(52) **U.S. Cl.**  
USPC ..... **562/466**(58) **Field of Classification Search**  
None  
See application file for complete search history.(56) **References Cited**

## U.S. PATENT DOCUMENTS

4,306,075	A	12/1981	Aristoff
4,424,376	A	1/1984	Moniot et al.
4,463,183	A	7/1984	Haslanger
4,486,598	A	12/1984	Aristoff
4,544,764	A	10/1985	Aristoff
4,668,814	A	5/1987	Aristoff
4,683,330	A	7/1987	Aristoff
5,039,814	A	8/1991	Shuman et al.
5,153,222	A	10/1992	Tadepalli et al.
6,054,486	A	4/2000	Crow et al.
6,441,245	B1	8/2002	Moriarty et al.
6,521,212	B1	2/2003	Cloutier et al.
6,528,688	B2	3/2003	Moriarty et al.
6,700,025	B2	3/2004	Moriarty et al.
6,756,033	B2	6/2004	Cloutier et al.
6,765,117	B2	7/2004	Moriarty et al.
6,803,386	B2	10/2004	Shorr et al.
6,809,223	B2	10/2004	Moriarty et al.
6,933,385	B2	8/2005	Westermann et al.
7,199,157	B2	4/2007	Wade et al.
7,384,978	B2	6/2008	Phares et al.
7,417,070	B2	8/2008	Phares et al.
7,999,007	B2	8/2011	Jeffs et al.
2002/0173672	A1	11/2002	Moriarty et al.

## FOREIGN PATENT DOCUMENTS

CA	2 710 726	A1	1/2012
CN	101891596	A	11/2010
CN	101891715	A	11/2010
EP	0 004 335	A2	10/1979
EP	0 087 237	B1	5/1986
EP	0 175 450	B1	3/1989
EP	0 159 784	B1	6/1989
EP	0 496 548	A1	7/1992
WO	WO 98/39337	A1	9/1998
WO	WO 99/21830	A1	5/1999
WO	WO 03/070163	A2	8/2003
WO	WO 2005/007081	A2	1/2005
WO	WO 2007/134292	A2	11/2007
WO	WO 2008/100977	A2	8/2008
WO	WO 2009/117095	A1	9/2009
WO	WO 2012/009816	A1	1/2012

## OTHER PUBLICATIONS

Alexander et al., "The Synthesis of Benzindene Prostacyclin Analogs as Potential Antiulcer Agents," *Prostaglandins*, 1986, 32(5):647-653.

Aristoff et al., "Synthesis and Structure-Activity Relationship of Novel Stable Prostacyclin Analogs," *Advances in Prostaglandin, Thromboxane, and Leukotriene Research*, Samuelsson et al., Eds., 1983, 11:267-274.

Aristoff et al., "Synthesis of Benzopyran Prostaglandins, Potent Stable Prostacyclin Analogs, Via an Intramolecular Mistunobu Reaction," *Tetrahedron Letters*, 1984, 25(36):3955-3958.

Aristoff et al., "Total Synthesis of a Novel Antiulcer Agent via a Modification of the Intramolecular Wadsworth-Emons-Wittig Reaction," *J. Am. Chem. Soc.*, 1985, 107:7967-7974.

Batra et al., "Crystallization Process Development for a Stable Polymorph of Treprostinil Diethanolamine (UT-15C) by Seeding," *Organic Process Research & Development*, 2009, 13:242-249.

(Continued)

*Primary Examiner* — Yevegeny Valenrod  
(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP

(57) **ABSTRACT**

This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.

**22 Claims, No Drawings**

## US 8,497,393 B2

Page 2

## OTHER PUBLICATIONS

- Belch et al., "Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1 Prodrug, in Patients with Intermittent Claudication," *Circulation*, May 6, 1997, 95(9):2298-2302.
- Chemburkar et al., "Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development," *Organic Process Research & Development*, 2000, 4:413-417.
- Chung et al., "Promoters for the (Alkyne)hexacarbonyldicobalt-Based Cyclopentenone Synthesis," *Organometallics*, 1993, 12:220-223.
- Clark et al., "High-Performance Liquid Chromatographic Method for Determining the Enantiomeric Purity of a Benzindene Prostaglandin by a Diastereomeric Separation," *Journal of Chromatography*, 1987, 408:275-283.
- Hardinger et al., "Triply-Convergent Syntheses of Two Homochiral Arene-Fused Prostacyclin Analogs Related to U68,215," *Bioorganic & Medicinal Chemistry Letters*, 1991, 1(1):79-82.
- Hicks et al., "A Practical Titanium-Catalyzed Synthesis of Bicyclic Cyclopentenones and Allylic Amines," *J. Org. Chem.*, 1996, 61:2713-2718.
- Jeong et al., "Catalytic Version of the Intramolecular Pauson-Khand Reaction," *J. Am. Chem. Soc.*, 1994, 116:3159-3160.
- Khand et al., "Organocobalt Complexes. Part II. Reaction of Acetylenehexacarbonyl-dicobalt Complexes,  $(R^1C_2R^2)Co_2(CO)_6$ , with Norbornene and its Derivatives," *J. Chem. Soc., J.C.S. Perkin I*, 1973, 977-981.
- Mathre et al., "A Practical Enantioselective Synthesis of  $\alpha,\alpha$ -Diaryl-2-pyrrolidinemethanol. Preparation and Chemistry of the Corresponding Oxazaborolidines," *J. Org. Chem.*, 1991, 56:751-762.
- Moriarty et al., "The Intramolecular Asymmetric Pauson-Khand Cyclization as a Novel and General Stereoselective Route to Benzindene Prostacyclins: Synthesis of UT-15 (Trepstinil)," *J. Org. Chem.* 2004, 69, 1890-1902.
- Mulzer et al., "Asymmetric Synthesis of Carbacyclin Precursors by Pauson-Khand Cyclization," *Liebigs Ann. Chem.*, 1988, 891-897.
- Nelson, Norman A., "Prostaglandin Nomenclature," *J. Med. Chem.*, Sep. 1974, 17(9):911-918.
- Pagenkopf et al., "Photochemical Promotion of the Intramolecular Pauson-Khand Reaction. A New Experimental Protocol for Cobalt-Catalyzed [2 +2+2+1] Cycloadditions," *J. Am. Chem. Soc.*, 1996, 118:2285-2286.
- Pagenkopf, Brian L., "Substrate and Reagent Control of Diastereoselectivity in Transition Metal-Mediated Process: Development of a Catalytic Photo Promoted Pauson-Khand Reaction," *Diss. Abstr. Int.*, 57(12):7535, 1977, Abstract.
- Paulson, Peter L., "The Khand Reaction," *Tetrahedron*, 1985, 41(24):5855-5860.
- Schore, Neil E., "Transition-Metal-Mediated Cycloaddition Reactions of Alkynes in Organic Synthesis," *Chem. Rev.*, 1988, 88:1081-1119.
- Shambayati et al., "N-Oxide Promoted Pauson-Khand Cyclizations at Room Temperature," *Tetrahedron Letters*, 1990, 31(37):5289-5292.
- Snell et al., "Investigating the Effect of Impurities on Macromolecule Crystal Growth in Microgravity," *Crystal Growth & Design*, 2001, 1(2):151-158.
- Sorbera et al., "UT-15. Treatment of Pulmonary Hypertension Treatment of Peripheral Vascular Disease," *Drug of the Future*, 2001, 26(4), 364-374.
- Takano et al., "Enantiodivergent Synthesis of Both Enantiomers of Sulcatol and Matsutake Alcohol from (R)-Epichlorohydrin," *Chemistry Letters*, 1987, 2017-2020.
- Viedma, Cristobal, "Selective Chiral Symmetry Breaking during Crystallization: Parity Violation of Cryptochiral Environment in Control?" *Crystal Growth & Design*, 2007, 7(3):553-556.
- Zhang et al., "A Nickel(0)-Catalyzed Process for the Transformation of Enynes to Bicyclic Cyclopentenones," *J. Org. Chem.*, 1996, 61:4498-4499.
- U.S. Appl. No. 13/409,685, filed Mar. 1, 2012, Sharma, Vijay.
- Comins et al., "Ortho Metalation Directed by  $\alpha$ -Amino Alkoxides," *J. Org. Chem.*, 1984, 49:1078-1083.
- Comins et al., "Ortho Substitution of M-Anisaldehyde via  $\alpha$ -Amino Alkoxide Directed Lithiation," *J. Org. Chem.*, 1989, 54:3730-3732.
- Corey et al., "Novel Electronic Effects of Remote Substituents on the Oxazaborolidine-Catalyzed Enantioselective Reduction of Ketones," *Tetrahedron Letters*, 1995, 36(50):9153-9156.
- Greene et al., "Protecting Groups," *Protective Groups in Organic Synthesis*, 2d. Ed., 1991, p. 1-11.
- Pansegrau et al., "The Oxazoline-Benzyne Route to 1,2,3-Trisubstituted Benzenes. Tandem Addition of Organolithiums, Organocuprates, and  $\alpha$ -Lithionitriles to Benzyne," *J. Am. Chem. Soc.*, 1988, 110:7178-7184.
- Rowley et al., "Application of the Pauson-Khand reaction to the synthesis of pentalenic acid," *Journal of Organometallic Chemistry*, 1991, 413:C5-C9.

US 8,497,393 B2

**1**  
**PROCESS TO PREPARE TREPROSTINIL,**  
**THE ACTIVE INGREDIENT IN**  
**REMODULIN®**

CROSS-REFERENCE TO RELATED  
 APPLICATIONS

This application is a Continuation of U.S. application Ser. No. 12/334,731, filed Dec. 15, 2008, which claims priority from U.S. Provisional Patent Application 61/014,232, filed Dec. 17, 2007, the entire contents of which are incorporated herein by reference.

BACKGROUND

The present invention relates to a process for producing prostacyclin derivatives and novel intermediate compounds useful in the process.

Prostacyclin derivatives are useful pharmaceutical compounds possessing activities such as platelet aggregation inhibition, gastric secretion reduction, lesion inhibition, and bronchodilation.

Treprostinil, the active ingredient in Remodulin®, was first described in U.S. Pat. No. 4,306,075. Treprostinil, and other prostacyclin derivatives have been prepared as described in Moriarty, et al in *J. Org. Chem.* 2004, 69, 1890-1902, *Drug of the Future*, 2001, 26(4), 364-374, U.S. Pat. Nos. 6,441,245, 6,528,688, 6,765,117 and 6,809,223. Their teachings are incorporated by reference to show how to practice the embodiments of the present invention.


U.S. Pat. No. 5,153,222 describes use of treprostinil for treatment of pulmonary hypertension. Treprostinil is approved for the intravenous as well as subcutaneous route, the latter avoiding septic events associated with continuous intravenous catheters. U.S. Pat. Nos. 6,521,212 and 6,756,033 describe administration of treprostinil by inhalation for treatment of pulmonary hypertension, peripheral vascular disease and other diseases and conditions. U.S. Pat. No. 6,803,386 discloses administration of treprostinil for treating cancer such as lung, liver, brain, pancreatic, kidney, prostate, breast, colon and head-neck cancer. U.S. patent application publication No. 2005/0165111 discloses treprostinil treatment of ischemic lesions. U.S. Pat. No. 7,199,157 discloses that treprostinil treatment improves kidney functions. U.S. patent application publication No. 2005/0282903 discloses treprostinil treatment of neuropathic foot ulcers. U.S. application Ser. No. 12/028,471 filed Feb. 8, 2008, discloses treprostinil treatment of pulmonary fibrosis. U.S. Pat. No. 6,054,486 discloses treatment of peripheral vascular disease with treprostinil. U.S. patent application Ser. No. 11/873,645 filed Oct. 17, 2007 discloses combination therapies comprising treprostinil. U.S. publication No. 2008/0200449 discloses delivery of treprostinil using a metered dose inhaler. U.S. publication No. 2008/0280986 discloses treatment of interstitial lung disease with treprostinil. U.S. application Ser. No. 12/028,471 filed Feb. 8, 2008 discloses treatment of asthma with treprostinil. U.S. Pat. No. 7,417,070, 7,384,978 and U.S. publication Nos. 2007/0078095, 2005/0282901, and 2008/0249167 describe oral formulations of treprostinil and other prostacyclin analogs.

Because Treprostinil, and other prostacyclin derivatives are of great importance from a medicinal point of view, a need exists for an efficient process to synthesize these compounds on a large scale suitable for commercial production.



SUMMARY

The present invention provides in one embodiment a process for the preparation of a compound of formula I, hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof.

2



The process comprises the following steps:  
 (a) alkylating a compound of structure II with an alkylating agent to produce a compound of formula III,



wherein

w=1, 2, or 3;

Y<sub>1</sub> is trans-CH=CH-, cis-CH=CH-, -CH<sub>2</sub>, (CH<sub>2</sub>)<sub>m</sub>-, or -C=C-; m is 1, 2, or 3;

R<sub>7</sub> is

(1) -C<sub>p</sub>H<sub>2p</sub>-CH<sub>3</sub>, wherein p is an integer from 1 to 5, inclusive,

(2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C<sub>1</sub>-C<sub>3</sub>) alkyl, or (C<sub>1</sub>-C<sub>3</sub>)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R<sub>7</sub> is phenoxy or substituted phenoxy, only when R<sub>3</sub> and R<sub>4</sub> are hydrogen or methyl, being the same or different,

(3) phenyl, benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C<sub>1</sub>-C<sub>3</sub>)alkyl, or (C<sub>1</sub>-C<sub>3</sub>)alkoxy, with the proviso that not more than two substituents are other than alkyl,

(4) cis-CH=CH-CH<sub>2</sub>-CH<sub>3</sub>,

(5) -(CH<sub>2</sub>)<sub>2</sub>-CH(OH)-CH<sub>3</sub>, or

(6) -(CH<sub>2</sub>)<sub>3</sub>-CH=C(CH<sub>3</sub>)<sub>2</sub>;

wherein -C(L<sub>1</sub>)-R<sub>7</sub> taken together is

(1) (C<sub>4</sub>-C<sub>7</sub>)cycloalkyl optionally substituted by 1 to 3 (C<sub>1</sub>-C<sub>3</sub>)alkyl;

(2) 2-(2-furyl)ethyl,

(3) 2-(3-thienyl)ethoxy, or

(4) 3-thionyloxymethyl;

M<sub>1</sub> is α-OH:β-R<sub>5</sub> or α-R<sub>5</sub>:β-OH or α-OR<sub>1</sub>:β-R<sub>5</sub> or α-R<sub>5</sub>:β-OR<sub>2</sub>, wherein R<sub>5</sub> is hydrogen or methyl, R<sub>2</sub> is an alcohol protecting group, and

L<sub>1</sub> is α-R<sub>3</sub>:β-R<sub>4</sub>, α-R<sub>4</sub>:β-R<sub>3</sub>, or a mixture of α-R<sub>3</sub>:β-R<sub>4</sub> and α-R<sub>4</sub>:β-R<sub>3</sub>, wherein R<sub>3</sub> and R<sub>4</sub> are hydrogen, methyl, or fluoro, being the same or different, with the

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.